Form 4: Guardant Health CIO Vests RSUs, Sells Shares for Tax

Guardant Health's Chief Information Officer, Kumud Kalia, reported the vesting of restricted stock units and the sale of shares to cover tax obligations.

Summary

• Kumud Kalia, Guardant Health's Chief Information Officer, reported multiple transactions on October 1, 2025, involving the vesting of restricted stock units (RSUs).
• Kalia acquired 1,607, 1,084, and 7,858 shares of common stock upon the vesting of these RSUs.
• Concurrently, 5,348 shares were disposed of at a price of $62.65 per share to satisfy tax withholding obligations related to the RSU vestings.
• Following these transactions, Kalia directly beneficially owns 24,365 shares of common stock.
• The filing also details remaining derivative holdings of 6,428, 4,335, and 15,956 restricted stock units.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction involving the vesting of restricted stock units and a tax-related share disposition, which is a neutral event for the company's operational or financial outlook.

Positives

• The vesting of restricted stock units represents a scheduled component of executive compensation, aligning management incentives with long-term company performance.
• The transactions reflect the execution of pre-established equity compensation plans.

Negatives

• A portion of vested shares, specifically 5,348 shares, was sold to cover tax liabilities, resulting in a reduction of direct beneficial ownership.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This is a routine insider transaction related to executive compensation, which is a standard practice across various industries to incentivize and retain key personnel. It does not provide specific insights into broader industry trends or competitive landscape.

Related Party Transactions

• The disposition of 5,348 shares to the company at $62.65 per share to meet tax withholding obligations related to RSU vesting constitutes a standard related-party transaction.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine compensation event and not indicative of a change in company fundamentals.
• Employees: Reflects standard executive compensation practices, which can be a factor in talent retention.

Next Steps

• The remaining 75% of the RSU award granted on November 7, 2022, will vest in equal quarterly installments over the remaining three-year period after October 1, 2023.
• The remaining 67% of the RSU award granted on December 13, 2023, will vest in equal quarterly installments over the remaining two-year period after October 1, 2024.
• The remaining 67% of the RSU award granted on November 8, 2024, will vest in equal quarterly installments over the remaining two-year period after October 1, 2025.

Key Dates

Recommendation

This Form 4 reports routine vesting of restricted stock units and the sale of shares to cover tax obligations by a company executive. Such transactions are common and do not typically indicate a change in the company's fundamental outlook or warrant a change in investment recommendation.

Keywords

Guardant Health, GH, SEC Form 4, insider trading, RSU, restricted stock units, stock vesting, executive compensation, Kumud Kalia